Jefferies Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Nalin Tejavibulya has maintained a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and increased the price target from $30 to $58.

April 01, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Nalin Tejavibulya reaffirmed a Buy rating on 4D Molecular Therapeutics and raised the price target from $30 to $58.
The upgrade in price target by a reputable analyst like Nalin Tejavibulya from Jefferies is a strong positive signal for the stock. It suggests a bullish outlook on the company's future performance and potential, likely leading to increased investor confidence and a positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100